Vepoloxamer

Drug Profile

Vepoloxamer

Alternative Names: ANX-188; CRL-5861; FLOCOR; MST-188; Poloxamer 188 NF; Purified 188; Purified poloxamer 188

Latest Information Update: 02 May 2017

Price : $50

At a glance

  • Originator CytRx Corporation
  • Developer Mast Therapeutics; Savara Pharmaceuticals
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Cell membrane structure modulators; Surface active agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders; Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Veno-occlusive disorders
  • Phase II Myocardial infarction
  • Preclinical Stroke
  • No development reported Acute lung injury; Cancer; CNS disorders; Muscular dystrophies; Peripheral nervous system diseases
  • Discontinued Chronic heart failure; Peripheral arterial occlusive disorders; Sickle cell anaemia

Most Recent Events

  • 27 Apr 2017 Mast Therapeutics has merged with Savara Pharmaceuticals and will operate under the name Savara Pharmaceuticals
  • 08 Nov 2016 Discontinued - Phase-II for Chronic heart failure in Australia (IV)
  • 08 Nov 2016 Discontinued - Phase-II for Chronic heart failure in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top